Silicosis Prevention Guidelines

Silicosis Prevention Guidelines

The National Institute for Occupational Safety and Health (NIOSH) offers several silicosis prevention guidelines to help workers reduce the likelihood of developing the condition. These silicosis prevention guidelines are largely geared toward industrial workers who are exposed to silica dust on a regular basis, including construction workers, cement and asphalt paving manufacturers, masons and concrete workers, miners, welders and other individuals in blue-collar occupations.

NIOSH’s silicosis prevention guidelines recommend that anyone who works with or around silica dust:

  • Wear appropriate protective gear, including a respirator, when working with silica products
  • Ensure proper ventilation in confined workspaces
  • Use dust collection systems and non-silica-containing abrasives to avoid exposing nearby workers to silica dust
  • Wash his or her hands before eating or drinking in the workplace
  • Shower and change into clean, noncontaminated clothing before leaving the worksite
  • Participate in routine health screenings to identify any abnormalities early on

While following these silicosis prevention guidelines can reduce a person’s risk of developing the disease, it does not eliminate the risk entirely. For this reason, it’s important to remain watchful for any potential symptoms, including chest pain, difficulty breathing and a chronic cough, even when following best practices for silicosis prevention. If any of these symptoms do develop, a physician can determine the underlying cause and provide individualized recommendations for treatment.

At the Lung Institute, we offer cellular therapy as an alternative therapy for silicosis. Unlike other treatments, which are only capable of reducing the symptoms of the disease, our cellular therapys have the potential to reduce inflammation and slow down the overall progression of the condition. These therapies, which are performed using a patient’s own cells, have helped many individuals improve their quality of life.

For more information about silicosis treatment options, contact the Lung Institute at (800) 729-3065. We have a caring team standing by to help you learn more about your diagnosis.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.